Treating Burkitt Lymphoma in Adults

Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice

(2015) Yinfei Tan et al.   CANCER BIOLOGY & THERAPY

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

(2014) David A. Rizzieri et al.   BRITISH JOURNAL OF HAEMATOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multifactorial Role for P. falciparum Malaria in Endemic Burkitt's Lymphoma Pathogenesis

(2014) Charles Torgbor et al.   PLoS Pathogens

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

(2013) A. M. Evens et al.   ANNALS OF ONCOLOGY

Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status

(2013) Josep-Maria Ribera et al.   CANCER

Low-Intensity Therapy in Adults with Burkitt's Lymphoma

(2013) Kieron Dunleavy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors

(2013) B Tolani et al.   ONCOGENE

Epidemiology: clues to the pathogenesis of Burkitt lymphoma

(2012) Ian Magrath   BRITISH JOURNAL OF HAEMATOLOGY

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

The genetic landscape of mutations in Burkitt lymphoma

(2012) Cassandra Love et al.   NATURE GENETICS

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

(2012)   NATURE GENETICS

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis

(2011) J. A. Barnes et al.   ANNALS OF ONCOLOGY

RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma

(2011) Gaetano Corazzelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

(2008) G. M. Mead et al.   BLOOD